Medical cosmetic research has already found that through regular treatments, rejuvenating Botox effects can last up to 7 months. A new study found that Botox has an anti-depressive effect on people with depressive disorders. Both men and women were considered in the randomized, double-blind, and placebo-controlled study. Six weeks after a single Botox treatment, participants reported a decrease in depression by nearly 50%, improving as the study and regular treatments continued. The researchers concluded that a regular Botox treatment "appears to induce a significant and sustained antidepressant effect in patients with major depression."
At Raval Facial Aesthetics, Dr. Raval says patients report positive feelings about his care-centered office after visiting on a regular schedule specific to them. Dr. Raval is board-certified by the American Board of Facial Plastic and Reconstructive Surgery. "As a surgeon, I know proactive and custom care is best, which is why I've always recommended regular visits," says Dr. Raval. "Regular visits might make people happier for other reasons as well," adds Dr. Raval about the study, "because my patients are more comfortable when I can get to know them individually on the treatment plan we develop. Of course, they also feel good about looking their best with safer and longer-lasting results."
Dr. Raval is medical director of Raval Facial Aesthetics and Rocky Mountain Laser Aesthetics, nominated for Best Medical Spa 2013 by the Denver A-List and winner of the Best of the Best in 2012 for Plastic and Cosmetic Surgeons as well as Excellence in Patient Satisfaction in 2011 and 2012. His office, located in Cherry Creek, is trusted leader in surgical and non-surgical rejuvenation procedures, like Dysport and Botox, and dermal fillers, like Juvederm and Radiesse.
For more information on the individual rejuvenating procedures offered by Raval Facial Aesthetics and Rocky Mountain laser Aesthetics, visit RavalMD.com (http://ravalmd.com/
Finzi, E., and Norman E. Rosenthal. (2013). Treatment of depression with onabotulinumtoxinA: